Pliant Therapeutics posted a net loss of $22.4 million for the quarter, down from $43.3 million a year earlier, widening its cash runway into the second half of 2028. The reduction reflects lower R&D and administrative spend, easing burn and giving investors a clearer path to value‑creating milestones.

Key Highlights

  • Net loss was $22.4 million
  • Cash and short-term investments total $159.6 million
  • Reported net loss of $22.4 million for the quarter ended June 30 2026.
  • Holds $159.6 million in cash, cash equivalents and short‑term investments.

Pliant Therapeutics (NASDAQ: PLRX) reported a net loss of $22.4 million for the quarter ended June 30, 2026.

Net Loss

The quarterly loss is a result of the company's operating expenses. General and administrative costs also fell.

Cash Position

With $159.6 million in cash, cash equivalents and short-term investments, Pliant can sustain its operations. This funds the ongoing Phase 1b FORTIFY expansion trial, which targets PLN-101095. The company is investigating PLN-101095 in the FORTIFY trial.

Market

Shares of Pliant Therapeutics are listed on the Nasdaq exchange under the ticker PLRX. The biotech sector is closely watching the development of integrin therapeutics. Pliant's lead program is PLN-101095, which is being investigated in the FORTIFY trial.

The potential benefits of PLN-101095 are still being studied.

Financials

The company's net loss was $22.4 million. The company has $159.6 million in cash, cash equivalents, and short-term investments.

Forward

The company will continue to develop PLN-101095. Enrollment continues in the FORTIFY trial. Pliant will provide more information on its platform soon.

The company is working on the development of its integrin-targeted drug-delivery platform.